{"title":"揭示铼-188微球与原发性肝癌细胞的相互作用:一项突破性研究","authors":"Aarti Aggarwal, Gurjeet Kaur, Ravjit Singh Jassal, Bikash Medhi, Bhagwant Rai Mittal, Jaya Shukla","doi":"10.1089/cbr.2023.0146","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Hepatocellular carcinoma is a prevalent contributor to global mortality rates. The main palliative treatments are trans-arterial chemoembolization and selective intra-arterial radionuclide therapy. <b><i>Methods:</i></b> A novel freeze-dried nonradioactive microsphere kit formulation has been developed, and the behavior and therapeutic potential of <sup>188</sup>Re microspheres have been assessed. The microspheres were labeled with fluorescein isothiocyanate (FITC) and <sup>188</sup>ReO<sub>4</sub><sup>-</sup>. The uptake of FITC microspheres by HepG2 cells was examined at various time intervals. The impact of <sup>188</sup>Re microspheres on cell viability and the mode of cell death were investigated with HepG2 cells using MTT and Annexin FITC-V/propidium iodide (PI) apoptosis assay. <b><i>Results:</i></b> The labeling efficiency of microspheres was more than 99% with FITC and <sup>188</sup>ReO<sub>4</sub><sup>-</sup>. The maximum uptake of FITC microspheres by HepG2 cells was achieved at 6 h. The exposure to <sup>188</sup>Re microspheres has shown a decrease in cellular viability from 77.81% ± 0.015% to 42.03% ± 0.148% at 192 h of incubation (∼11 half-lives). The cellular uptake of <sup>188</sup>Re microspheres was 0.255-0.901 MBq. These values were concordant with Annexin FITC-V/PI apoptosis assay. At 192 h, 53.28% ± 0.01% of cells entered the apoptotic phase after treatment with <sup>188</sup>Re microspheres, and only 39.34% ± 0.02% of cells remained viable. However, in the cells treated with <sup>188</sup>ReO<sub>4</sub><sup>-</sup> alone, 74.86% ± 0.005% of cells were viable, and only 24.75% ± 0.577% of cells were in the early apoptotic phase at 192 h. <b><i>Conclusion:</i></b> The data revealed that <sup>188</sup>Re microspheres treatment led to significant growth inhibition in HepG2 cells compared with <sup>188</sup>ReO<sub>4</sub><sup>-</sup>.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"188-195"},"PeriodicalIF":2.4000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035844/pdf/","citationCount":"0","resultStr":"{\"title\":\"Unraveling Interaction of Rhenium-188 Microspheres with Primary Hepatic Cancer Cell: A Breakthrough Study.\",\"authors\":\"Aarti Aggarwal, Gurjeet Kaur, Ravjit Singh Jassal, Bikash Medhi, Bhagwant Rai Mittal, Jaya Shukla\",\"doi\":\"10.1089/cbr.2023.0146\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Introduction:</i></b> Hepatocellular carcinoma is a prevalent contributor to global mortality rates. The main palliative treatments are trans-arterial chemoembolization and selective intra-arterial radionuclide therapy. <b><i>Methods:</i></b> A novel freeze-dried nonradioactive microsphere kit formulation has been developed, and the behavior and therapeutic potential of <sup>188</sup>Re microspheres have been assessed. The microspheres were labeled with fluorescein isothiocyanate (FITC) and <sup>188</sup>ReO<sub>4</sub><sup>-</sup>. The uptake of FITC microspheres by HepG2 cells was examined at various time intervals. The impact of <sup>188</sup>Re microspheres on cell viability and the mode of cell death were investigated with HepG2 cells using MTT and Annexin FITC-V/propidium iodide (PI) apoptosis assay. <b><i>Results:</i></b> The labeling efficiency of microspheres was more than 99% with FITC and <sup>188</sup>ReO<sub>4</sub><sup>-</sup>. The maximum uptake of FITC microspheres by HepG2 cells was achieved at 6 h. The exposure to <sup>188</sup>Re microspheres has shown a decrease in cellular viability from 77.81% ± 0.015% to 42.03% ± 0.148% at 192 h of incubation (∼11 half-lives). The cellular uptake of <sup>188</sup>Re microspheres was 0.255-0.901 MBq. These values were concordant with Annexin FITC-V/PI apoptosis assay. At 192 h, 53.28% ± 0.01% of cells entered the apoptotic phase after treatment with <sup>188</sup>Re microspheres, and only 39.34% ± 0.02% of cells remained viable. However, in the cells treated with <sup>188</sup>ReO<sub>4</sub><sup>-</sup> alone, 74.86% ± 0.005% of cells were viable, and only 24.75% ± 0.577% of cells were in the early apoptotic phase at 192 h. <b><i>Conclusion:</i></b> The data revealed that <sup>188</sup>Re microspheres treatment led to significant growth inhibition in HepG2 cells compared with <sup>188</sup>ReO<sub>4</sub><sup>-</sup>.</p>\",\"PeriodicalId\":55277,\"journal\":{\"name\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"volume\":\" \",\"pages\":\"188-195\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035844/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Biotherapy and Radiopharmaceuticals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/cbr.2023.0146\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2023.0146","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Unraveling Interaction of Rhenium-188 Microspheres with Primary Hepatic Cancer Cell: A Breakthrough Study.
Introduction: Hepatocellular carcinoma is a prevalent contributor to global mortality rates. The main palliative treatments are trans-arterial chemoembolization and selective intra-arterial radionuclide therapy. Methods: A novel freeze-dried nonradioactive microsphere kit formulation has been developed, and the behavior and therapeutic potential of 188Re microspheres have been assessed. The microspheres were labeled with fluorescein isothiocyanate (FITC) and 188ReO4-. The uptake of FITC microspheres by HepG2 cells was examined at various time intervals. The impact of 188Re microspheres on cell viability and the mode of cell death were investigated with HepG2 cells using MTT and Annexin FITC-V/propidium iodide (PI) apoptosis assay. Results: The labeling efficiency of microspheres was more than 99% with FITC and 188ReO4-. The maximum uptake of FITC microspheres by HepG2 cells was achieved at 6 h. The exposure to 188Re microspheres has shown a decrease in cellular viability from 77.81% ± 0.015% to 42.03% ± 0.148% at 192 h of incubation (∼11 half-lives). The cellular uptake of 188Re microspheres was 0.255-0.901 MBq. These values were concordant with Annexin FITC-V/PI apoptosis assay. At 192 h, 53.28% ± 0.01% of cells entered the apoptotic phase after treatment with 188Re microspheres, and only 39.34% ± 0.02% of cells remained viable. However, in the cells treated with 188ReO4- alone, 74.86% ± 0.005% of cells were viable, and only 24.75% ± 0.577% of cells were in the early apoptotic phase at 192 h. Conclusion: The data revealed that 188Re microspheres treatment led to significant growth inhibition in HepG2 cells compared with 188ReO4-.
期刊介绍:
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.